Maravai LifeSciences Holdings Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $208.8M-19.4% YoYTTM through 30 Jun 2026
Net Income -$77.4MTTM through 30 Jun 2026
Free Cash Flow -$35.8MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 51.2% |
| EBITDA Margin | -32.3% |
| Operating Margin | -3.8% |
| Net Margin | -37.1% |
Returns
-28.3%ROE
-14.7%ROA
Balance Sheet Health
Debt / Equity0.65x
Current Ratio5.91x
Net Debt$75.1M
Cash & Equivalents$70.1M
Quality Metrics
Altman Z-Score6.61
Piotroski F-Score3 / 9
FCF Margin-17.2%
Rule of 40-15.8
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $185.7M
Diluted EPS-$0.53TTMFY2025: $-0.91
Dividend
No dividend
Capital Allocation
R&D Spend$15.2M
Capex Intensity5.1%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| TriLink | $47.5M | +65.1% | View detailsExpected to benefit from the opening of the new GMP Enzyme Manufacturing Facility in June 2026, enabling integrated IVT supply from R&D to commercial scale. |
| Cygnus | $18.4M | +1.4% | View detailsExpected to maintain low to mid-single-digit growth overall, supported by MockV viral clearance kits and host cell protein (HCP) kits. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.